Comparing a remote patient monitoring company (RSH) with recurring revenue of about $600k a month and growing fast is very different to a biotech dependant on trials.
so
@AlCp once again your best insight is that IMU can’t do phase 3 trials and they are waiting for big pharma to take them out and you can’t even compare apples with apples when it comes to your constant mention of other companies.
I didn’t know the CEO takes $2.5m in salary - I can see why the voting was so strongly against the board at the last AGM.
I’m looking at IMU and I’m trying to ascertain the potential risk / reward - I’m just finding it difficult to get a feel for the probably of success - to those biotech experts can you share your thoughts on the ‘probability of commercially significant results ‘?
(20min delay)